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Summary: A solubilized hepatic microsomal enzyme system 
previously shown to catalyze the w-hydroxylation of fatty 
acids also catalyzes the hydroxylation of drugs. Benzphetamine, 
aminopyrine, ethylmorphine, hexobarbital, norcodeine, and 
p-nitroanisole undergo aerobic demethylation in the presence 
of NADPH and the resolved enzyme system. The required 
submicrosomal components for benzphetamine demethylation, 
as determined either by formaldehyde liberation or by NADPH 
oxidation, are cytochrome P-450, NADPH-cytochrome P-450 
reductase, and a heat-stable lipid fraction. Similar re- 
quirements were shown for the oxidation of aminopyrine, 
ethylmorphine, and hexobarbital. Laurate and benzphetamine 
were found to be mutually inhibitory, as would be expected if 
a common "methyl hydroxylase" were involved. The solubilized 
cytochrome P-450 preparation exhibits a difference spectrum 
in the presence of benzphetamine with a peak at 392 ml and 
a trough at 427 rnp and difference spectra with aniline and 
hexobarbital typical of those obtained with the microsomal 
bound .form of this hemoprotein. 
Cytochrome P-450, the carbon monoxide-binding pigment 
of microsomes (l), serves as a mixed function oxidase effect- 
ing the hydroxylation of steroids and the oxidative demethyla- 
tion and hydroxylation of drugs in animal tissues (2-4). 
Attempts to solubilize this pigment by a variety of tech- 
niques resulted in the extensive formation of P-420 (l), 
an altered form possessing no catalytic activity. Recent 
studies in our laboratory on the w-hydroxylation of fatty 
acids in liver microsomes led to "solubilization" of the enzyme 
system by the criterion that enzymatic activity remained in 
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the supernatant fraction upon prolonged centrifugation at 
105,000 x g (5,6). Resolution of the soluble system yielded 
the following fractions, all necessary for fatty acid hydroxy- 
lation to occur at a maximal rate in the presence of NADPH and 
molecular oxygen: cytochrome P-450, NADPH-cytochrome P-450 
reductase, and a heat-stable component. Such preparations of 
P-450 exhibit a CO difference spectrum and an electron para- 
magnetic resonance spectrum (7) similar to those previously 
attributed to the microsome-bound form. Whereas a soluble form 
of cytochrome P-450 is functional in camphor hydroxylation in 
enzyme preparations from Pseudomonas putida (8), the w-hydroxy- 
lation system of Pseudomonas oleovorans does not require this 
pigment (9). 
In the present paper evidence is presented that our 
"soluble" P-450 preparation combines with drugs, as judged by 
the resulting difference spectra, and catalyzes their demethy- 
Table I 
Drug oxidation in resolved enzyme system from liver microsomes 
Expt. Substrate Additions 
No. 
Formaldehyde % Maximal 
formed (nmoles) activity 
1 Benzphetamine 234 100 
Aminopyrine 95 41 
Ethylmorphine 85 36 
Hexobarbital 62 26 




" (4 x 123 M) 





The complete reaction mixture contained 150 pmoles of 
phosphate buffer, pH 7.5, 10 pmoles of YgCl 5 Fmoles of semi- 
carbazide, 0.5 pmole of NADPH, the drug in icated (1.5 Fmoles a! 
of benzphetamine or ethylmorphine, 6.0 of aminopyrine, or 4.0 
of hexobarbital), cytochrome P-450 (0.56 nmoles), and, in the 
two experiments, reductase fraction (0.37 and 0.34 mg of protein, 
respectively), and lipid (0.10 and 0.15 mg, respectively), 
in a final volume of 1.5 ml. After incubation for 20 min at 30" 
the reaction mixtures were deproteinized and analyzed for 
formaldehyde by the method of Nash (10) as modified by Cochin 
and Axelrod (11). 
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lation in the presence of other microsomal components. Under 
optimal conditions benzphetamine is a better substrate than 
laurate. Of particular interest, a microsomal lipid component 
is necessary for drug demethylation as well as for fatty acid 
w-hydroxylation. 
Evidence for the demethylation of various drugs, resulting 
in the production of formaldehyde, is presented in Table I. 
The microsomal fractions were prepared as described earlier 
(7), optimal resolution being obtained by preparing the P-450 
and lipid fractions from liver microsomes of rabbits induced 
with phenobarbital and the reductase from liver microsomes of 
rats which had been administered 7.5 mg of phenobarbital and 
5 mg of hydrocortisone per 100 g of body weight at three 8- 
hour intervals, resulting in a 4-to 5-fold increase in this 
enzyme,, Of the four N-methyl compounds tested, benzphetamine 
was hydroxylated most rapidly; the oxidation of this drug in 
microsomal suspensions has recently been reported by others 
(12,13). In other experiments not shown here, two O-methyl 
compounds, norcodeine and p-nitroanisole, were demethylated about - 
28% as rapidly as benzphetamine. As shown in Expt. 2, laurate 
is an effective inhibitor of benzphetamine oxidation, and in 
other experiments laurate hydroxylation was found to be inhibited 
by the N-methyl compounds (0.01 M) as follows: aminopyrine 
(ls), ethylmorphine (4%), aniline (54%), benzphetamine (58%), 
and hexobarbital (6%). Although these results suggest that a 
single form of P-450 may catalyze both drug and fatty acid hy- 
droxylation, a final conclusion must await purification of this,, 
solubilized pigment. 
Similar conclusions were reached when the hydroxylation 
reaction was determined by following the disappearance of NADPH 
at 340 rnp (Fig. 1). Benzphetamine was clearly the best sub- 
strate,, with the other drugs being hydroxylated at lower, but 
significant rates. When determined under similar conditions, 
with benzphetamine as the substrate, NADPH disappearance and 
formaldehyde liberation occurred in the molar ratio of 0.9, con- 
forming to the stoichiometry expected of a mixed function oxi- 
dase. 
The demethylation of benzphetamine was found to require the 
same three microsomal components as does laurate w-hydroxyla- 
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Fig. 1. NADPH disappearance as a function of time in 
reaction mixtures similar to those described in the legend to 
Table I, but in a final volume of 1.0 ml. The reaction mixtures 
contained P-450 (0.18 nmole), reductase (0.074 mg of protein), 
and lipid (0.1 mg). After the final addition of NADPH, the 
reaction mixtures were allowed to equilibrate for 2 min at 
30°, and the absorbance at 340 rnp was then recorded at the same 
temperature with a spectrophotometer equipped with a Gilford 
multiple sample absorbance recorder. Curves 1 to 4 were obtained 
with 1 mM benzphetamine, 5 mM aminopyrine (or 2 mM hexobarbi- 
tal), 1 iiiM ethylmorphine, and no substrate, respectively. - 
tion, as shown in Table II. Similar results were obtained 
whether NADPH oxidation or formaldehyde formation was determined. 
Because of the presence of small amounts of P-450 in the reduc- 
Table II 
Requirements for benzphetamine hydroxylation 
System Formaldehyde 
formed 






NO P-450 fraction 
No reductase fraction 





NADPH disappearance was estimated spectrophotometrically 
at 340 rnp and formaldehyde formation was measured by the Nash 
method in reaction mixtures containing 1 mM benzphetamine but 
otherwise similar to those described in ts legend to Table I. 
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tase fraction, a complete dependence on P-450 was not observed. 
In similar experiments not shown here, the hydroxylation of 
aminopyrine, hexobarbital, and ethylmorphine was also found to 
require the presence of the lipid component. 
As reported by others, hepatic microsomal bound P-450 
exhibits spectral shifts upon the addition of certain hydroxylata- 
ble substrates (14-16). We have recently described a Type I 
difference spectrum resulting from the addition of laurate to 
the soluble P-450 preparation (7). Upon the addition of benzpheta- 
mine, as shown in Fig. 2, the soluble preparation gave a differ- 
ence spectrum with a peak at about 392 nyr and a trough at 427 mn 
which may also be classified as Type I. The difference spectra 
recorded with hexobarbital and with aniline are typical of those 
obtained with microsomal suspensions. These results indicate 
that our P-450 preparation retains the binding properties of "the 
microsomal form. 
The cytochrome P-450-containing hydroxylation system of 
liver microsomes has unusually broad specificity, acting on 
fatty acids (5,7,17,18), alkanes (7,17), various steroids 
(19-21), carcinogenic polycyclic hydrocarbons (22), and a host 
of drugs and related substances (22,23). Although the exis- 
tence of multiple distinct forms would account for the broad 
WAVELENGTH (mrl 
F%* 2- 5 x lo- Difference spectra due to the3presence of M benzphetam$ie (Curve A), 5 x 10 M hexobarbital 
(Curve B), or 5 x 10 M aniline (Curve C) in-a soluble 
preparation of cytochroGe P-450 (1.5 nmoles; 0.91 mg of protein 
per ml) in phosphate buffer, pH 7.7. 
549 
Vol. 36, No. 4, 1969 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
specificity, no more than one form of P-450 has been identi- 
fied with certainty by spectral methods (24,25). Evidence that 
such factors as sex, age, species, and drug induction have sim- 
ilar effects on the steroid- and drug-metabolizing activities of 
liver microsomes has been presented by Kuntzman et al. (26). -- 
Moreover, kinetic data have been reported by Rubin et al. (27) -- 
showing that drugs are mutually competititive and by Tephly and 
Mannering (28) indicating that steroids competitively inhibit 
the oxidation of drugs. More recently, George and Tephly (29) 
have reported that different rate-controlling events occur in 
the N- and 0-dealkylation of morphine analogs, but that both re- 
quire cytochrome P-450. The evidence in the present paper that 
drug demethylation and fatty acid w-hydroxylation require the 
same submicrosomal components also provides no indication for 
more than one form of P-450 or "methyl hydroxylase". The pos- 
sibility may also be considered that lipids affect the speci- 
ficity of cytochrome P-450. The identity and role of the 
microsomal lipid factor (or factors) required for the hydroxy- 
lation of fatty acids and drugs in the resolved microsomal system 
are presently under investigation. 
Acknowledgments: Norcodeine was kindly furnished by Dr. 
T. R. Tephly, ethylmorphine and aminopyrine by Dr. II. A. 
Sasame, and benzphetamine by Dr. J. W. Hinman and Dr. F. F. 











(Xnura, T., and Sato, R., J. Biol. Chem., 237, PC1375 
(1962). 
Estabrook, R. W., Cooper, D. Y., and Rosenthal, O., 
Biochem. Z., 338, 741 (1963). 
Cooper, D. Y., Levin, S., Narasimhulu, S., Rosenthal, O., 
and Estabrook, R. W., Science, 147, 400 (1965). 
Cmura, T., Sato, R., Cooper, D. Y., Rosenthal, O., and 
Estabrook, R. W., Fed. Proc., 24, 1181 (1965). 
Lu, A. Y. H., and Coon, M. J., J. Biol. Chem., 237, 1331 
(1968). 
Coon, M. J., and Lu, A. Y. H., in J. R. Gillette et al. 
(editors), Microsomes and Drug Oxidations, AcademE Press, 
New York, 1969, p. 151 
Lu, A. Y. H., Junk, K.-W., and Coon, M. J., J. Biol. 
Chem., In press (1969). 
Katagiri, M., Ganguli, B. N., and Gunsalus, I. C., J. 
Biol. Chem., 243, 3543 (1968). 
McKenna,E. J., and Coon, M. J., Abstracts, American 
Chemical Society, 156th Meeting, Atlantic City, Sept. 
(1968), No. 61. 
550 





















Nash, T., Biochem. J., 55,416 (1953). 
Cochin, J., and Axelrod, J., J. Pharmacol. Exp. Therap., 
125, 105 (1959). -- Hewick, D. S., and Fouts, J. R., Fed. Proc., 28, 483 
(1969). 
Harbison, R. D., Eling, T. E., and Becker, B. A., Fed. 
Proc., 28, 676 (1969). 
Estabrook, R. W., Schenkman, J. B., Cammer, W., Remmer, 
H ., Cooper, D. Y., Narasimhulu, S., and Rosenthal, O., 
in Chemical and Biological Aspects of Gxygenases, Bloch, 
K ., and Hayaishi, 0. (eds.), Maruzen Co., Tokyo, 1967, 
p. 153. 
Sato, R., in Chemical and Biological Aspects of Gxygenases, 
Bloch, K., and Hayaishi, O., (eds.), Maruzen Co., Tokyo, 
1967, p. 195. 
Schenkman, J. B., Remmer, H., and Estabrook, R. W., 
Mol. Pharmacol ., 3, 113 (1967). 
Das, M. L., Grrenius, S., and Ernster, L., European J. 
Biochem., 4, 519 (1968). 
Wada, F., Shibata, H., Goto, M., and Sakamoto, Y., Biochim. 
Biophys. Acta, 162, 518 (1968). 
Talalay, P., Ann. Rev. Biochem., 34, 347 (1965). 
Conney, A. H., Levin, W., Ikeda, M., Kuntzman, R., 
Cooper, D. Y., and Rosenthal, O., J. Biol. Chem., 243, 
3912 (1968). 
Voigt, W., Thomas, P. J., and Hsia, S. L., J. Biol. Chem., 
243, 3493 (1968). 
Eney, A. H., Pharmacol. Rev., 19, 317 (1967). 
Gillette, J. R., Advan. Pharmacoc, 4, 219 (1966). 
Hildebrandt, A., Remmer, H., and Estabrook, R. W., Bio- 
them. Biophys. Res. Commun., 30, 607 (1968). 
Schenkman, J. B., Greim, H., Zange, M., and Remmer, H., 
13iochim. Biophys. Acta, 171, 23 (1969). 
Kuntzman, R., Jacobson, M., Schneidman, K., and Conney, 
A. H., J. Pharmacol. Exp. Therap., 146, 280 (1964). 
Rubin, A., Tephly, T. R., and Mannesg, G. J., Biochem. 
pharmacol., 13, 1007 (1964). 
Tephly, T. R., and Mannering, G. J., Mol. Pharmacol., 
4, 10 (1968). 
George, W. J., and Tephly, T. R., Mol. Pharmacol., 4, 
!302 (1968). 
551 
